Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Salutsantjoan     Gmail     Dropbox     Instagram     Google Drive     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon


My photo
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com




Sunday, January 3, 2021

REGN-COV2 (Regeneron)

REBEL EM - January 02, 2020 - By Anand Swaminathan
Paper: Weinreich DM et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19. NEJM 2020. PMID: 33332778 Free Link Clinical Trials Listing
"Clinical Question: Does REGN-COV2 reduce viral loads, lead to improvements and reduce medical attendance in outpatients with COVID19?
Author Conclusion: “In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group.”
Our Conclusions: No conclusions can be drawn from a study published with no hypothesis. Our stance is that this cocktail, as with other monoclonal antibodies, should ONLY be given to patients in the setting of a clinical trial. On a related note, the NEJM is no longer a reliable, trusted source of high-quality clinical information.
Clinical Take Home Point: There is no role for the use of REGN-COV2 outside of a clinical trial. A large, well-done, preferably non-industry sponsored trial is necessary prior to this drug being used outside of this setting."